Archive · 28 Dec 2025
New Drug Shows Promise in Treating Male Baldness
Cosmo Pharmaceuticals has announced promising results from two large phase 3 trials for a new drug called clascoterone.
This drug is designed to help men with hair loss by blocking a hormone called DHT directly at the hair follicles, which is different from how current treatments work.
The trials showed that the drug can significantly increase hair growth and is generally safe to use.
If approved, it could be a new option for men who haven't had success with existing treatments or who want to avoid systemic side effects.
The company plans to submit the drug for regulatory approval in the US and Europe by spring 2026.
Cosmo Pharmaceuticals announced positive phase 3 trial results for clascoterone 5 per cent topical solution in treating male baldness.
The drug works by blocking androgen receptors locally at hair follicles, offering a new mechanism of action.
Trials showed statistically significant hair growth and positive patient-reported outcomes.
The safety profile was encouraging, with no meaningful systemic androgen blockade.
Regulatory filings in the US and Europe are expected by spring 2026, pending full 12-month safety data.
- Who
- Cosmo Pharmaceuticals
- What
- Phase 3 trial results for clascoterone 5 per cent topical solution for male baldness
- When
- Results announced, full 12-month safety follow-up by spring 2026
- Where
- Trials conducted in the United States and Europe
- Why
- To provide a new treatment option for male androgenetic alopecia with a novel mechanism of action
- Drug Name
- Clascoterone 5 per cent topical solution
- Developer
- Cosmo Pharmaceuticals
- Condition Treated
- Male androgenetic alopecia (AGA)
- Mechanism
- Blocks androgen receptors locally at hair follicles
- Trial Results
- Statistically significant hair growth in phase 3 trials
- Safety Profile
- Comparable adverse events to vehicle, no systemic androgen blockade
- Regulatory Timeline
- Expected filings in US and Europe by spring 2026
